Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abacavir + lamivudine + zidovudine + lopinavir + ritonavir + cyclosporine + sargramostim + peginterferon alfa + aldesleukin
- Development stage
- Unknown
- Lead developer
- Juan A. Arnaiz
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This combination therapy, evaluated in the PHI-IMD clinical trial (NCT00114153) led by Juan A. Arnaiz, is an experimental regimen for primary HIV-1 infection. It consists of a standard Highly Active Antiretroviral Therapy (HAART) backbone—comprising Trizivir (abacavir, lamivudine, and zidovudine) and Kaletra (lopinavir and ritonavir)—augmented with an immune-based therapy. The immunotherapy components include cyclosporine A, granulocyte-macrophage colony-stimulating factor (GM-CSF), pegylated-interferon-alpha, and low-dose interleukin-2 (IL-2). The regimen is designed to suppress viral replication while simultaneously stimulating a robust, HIV-specific immune response, with the ultimate goal of achieving sustained viral control in the absence of ongoing antiretroviral treatment.
- Brand names
- TrizivirKaletra
- Other names
- HAART + ImmunotherapyHAART-Juan A. Arnaiz-HIV infection
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseCYP3A4 (Cytochrome P450 3A4)CN (Calcineurin)PR (Progesterone receptor)
Beyond the preview
Go deeper on abacavir + lamivudine + zidovudine + lopinavir + ritonavir + cyclosporine + sargramostim + peginterferon alfa + aldesleukin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abacavir + lamivudine + zidovudine + lopinavir + ritonavir + cyclosporine + sargramostim + peginterferon alfa + aldesleukin.